Gastroenterology

At the 2022 AAP National Conference & Exhibition, a practitioner shares her expertise on how to communicate with families to manage a child’s eating disorder (ED) and review practical strategies while increasing patient and family satisfaction.

At the American Academy of Pediatrics National Conference & Exhibition, Cassandra Padgett, MS, ACE health coach, discussed how telemedicine intervention effectively managed obesity in pediatric patients during the COVID-19 pandemic.

The ActiveBrains trials associated exercise with improved intelligence and cognitive function in overweight or obese children.

Dr. Gregory Weiss reflects on a recent literature review breaking down different subtypes of pediatric obesity.

Small shifts in your communication style and tactics when discussing obesity with patients can significantly impact how your message is received.

VIVUS LLC announced the US Food and Drug Administration's approval of QSYMIA (phentermine and topiramate extended-release capsules) for the treatment of obesity in adolescents ages 12 to 17 years.

Based on an investigation of associations between patterns of growth in infant weight and adult-onset coronary heart disease, the answer seems to be no.

Recently, the FDA announced the approval of supplemental indication for phentermine and topiramate extended-release capsules for chronic weight management in children aged 12 years and older.

Data from Morbidity and Mortality Weekly Report showed that there was no demonstrated increase in pediatric hepatitis or adenovirus 40/41 above pre-COVID-19 pandemic baseline levels.

Results of a study in patients with Hirschsprung disease for whom surgery was anticipated but had not yet been performed found that 17% developed complications.

The overall strength of association was directly related to the number of affected first-degree relatives and was modified by IBD subtype and age of diagnosis.

At the 2022 Pediatric Academic Societies Meeting, Marisa Stahl, MD, MSCS, discussed how to separate the wheat from the chaff when it comes to the gluten epidemic.

At the Pediatric Academic Societies Meeting 2022, Alexandra Russell, MD discusses best complementary and alternative medicines for pediatric gastrointestinal disorders.

Two pediatric health care providers offer best practices for treating patients with obesity.

The administration of rapid intravenous fluid is the current practice for acute gastroenteritis, but does it actually lead to better outcomes?

School nurses and nurse practitioners play an important role in assessing the child’s health status related to obesity, potential for co-morbidities, and implementing appropriate management strategies.

A female aged 13 years with morbid obesity and recent hospitalization for pyelonephritis presents with abdominal pain, tachycardia, and shortness of breath. What's the diagnosis?

As we begin to emerge from the national lockdown due to the COVID-19 pandemic, many pediatricians may find that the already widespread problem of youth-onset obesity is worse than ever.

Gastrointestinal concerns are a common reason for a child's visit. This article offers a review of the most common ailments that may lead to that visit.

An investigation examines whether ultraprocessed foods are linked to worse adiposity trajectories than diets with less processed foods.

Becoming overweight at a young age can lead to long-term obesity and represents an important challenge to tackle in childhood. An investigation looks at the impact of a health literacy intervention on reducing overweight children.

Often used to treat gastrointestinal concerns in children, proton pump inhibitors are thought to lead to respiratory concerns. A study examines this association.

The American Academy of Pediatrics (AAP) offers guidance on continuing obesity management during the current pandemic.

A 6 minute test is frequently used to test a child's ability to tolerate exercise, but a study investigates if a 3 minute test could work just as well.

US Food and Drug Administration (FDA) has approved an updated label for liraglutide for its use in adolescents aged 12 to 17 years.